Objective: To investigate the prognostic value of postoperative serum carcinoembryonic antigen(CEA) combined with carbohydrate antigen 19-9(CA19-9), human chondroglycoprotein(YKL-40), C-reactive protein(CRP) and interleukin 6(IL-6) in patients with colorectal cancer(CRC) after radical resection. Methods: A total of 441 CRC patients who received radical surgical treatment in our hospital from January 2010 to February 2017 were selected as the objects of this study. The levels of serum CEA, CA19-9, YKL-40, CRP and IL-6 were measured before adjuvant chemotherapy. The patients were followed up until November 2021 or at the time of death. Cox regression proportional risk model and Kaplan-Meier survival curve were used to analyze the risk factors for postoperative recurrence and survival. Receiver operating characteristic(ROC) curve was used to analyze the diagnostic or prognostic efficacy of serological indicators for CRC. Results: The sensitivity, pecificity and positive predictive value(PPV) of postoperative serum CEA in predicting the recurrence were 21.3%, 90.3% and 80.3% respectively. The sensitivity and PPV of postoperative serum CEA>5 μg·L-1 combined with CA19-9, YKL-40, CRP and IL-6 in predicting the recurrence were increased(P<0.05). For patients with postoperative serum CEA ≤ 5 μg·L-1, 10-year overall survival(OS) and disease-free survival(DFS) of patients with serum YKL-40>77.9 ng·ml-1 were shorter than those with serum YKL-40 ≤ 77.9 ng·ml-1(P<0.05). In addition, the 10-year OS of patients with serum CRP>2.99 mg·L-1 was shorter than that of patients with CRP ≤ 2.99 mg·L-1(P<0.05). The 10-year DFS of patients with serum IL-6>5.4 pg·ml-1 was shorter than that of patients with IL-6 ≤ 5.4 pg·ml-1(P<0.05). Cox regression proportional risk model analysis showed that the increase of CEA, CA19-9, YKL-40 and IL-6 were independent risk factors affecting OS, while the increase of CEA, YKL-40 and IL-6 were independent risk factors affecting DFS(P<0.05). Conclusion: Serum CEA combined with CA19-9, YKL-40, CRP and IL-6 after radical resection can be used as prognostic indicators for colorectal cancer recurrence and survival.
 方敏, 吕嘉晨.结直肠癌筛查的现状、进展及问题思考[J].医学与哲学, 2021, 42(11):17-22.
 林宇挺, 熊海林.Ⅱ~Ⅲ期结直肠癌中Vasohibin-1的表达及复发转移预后分析[J].中国肿瘤外科杂志, 2021, 13(5):484-488.
 GAO Y, WANG J, ZHOU Y, et al. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer[J].Sci Rep, 2018, 8(1):2732-2740.
 KONISHI T, SHIMADA Y, HSU M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome[J].JAMA Oncol, 2018, 4(3):309-315.
 SJIN J K, KIM H C, LEE W Y, et al. High preoperative serum CA 19-9 levels can predict poor oncologic outcomes in colorectal cancer patients on propensity score analysis[J].Ann Surg Treat Res, 2019, 96(3):107-115.
 王逸君, 张碧云, 陈乐君, 等.炎症及营养指标与直肠癌新辅助放化疗病理反应及患者预后的相关性研究[J].东南大学学报(医学版), 2021, 40(5):578-585.
 HERMUNEN K, SOVERI L M, BOISEN M K, et al. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer[J].Acta Oncol, 2020, 59(12):1416-1423.
 EBRAHIM A, MUSTAFA A I, EL-SHIMI O S, et al. Serum YKL40:a novel potential link between inflammation and dyslipidemia in acne vulgaris[J].J Cosmet Dermatol, 2020, 19(5):1219-1223.
 MILONE M, DESIDERIO A, VELOTTI N, et al. Surgical stress and metabolic response after totally laparoscopic right colectomy[J].Sci Rep, 2021, 11(1):9652-9662.
 NASR R, SALIM HAMMOUD M, NASSAR F, et al. Inflammatory markers and microRNAs:the backstage actors influencing prognosis in colorectal cancer patients[J].Int J Mol Sci, 2018, 19(7):1867-1880.
 杨晓飞, 于丽娜, 刘京. 肿瘤标志物、血清炎症因子和协同共刺激分子B7-H6的表达在宫颈癌中的临床价值研究[J].现代医学, 2021, 49(11):1267-1272.
 郭庆伟, 徐志诚, 崔永欣. 结直肠癌术前不同CEA水平对患者预后及复发转移的影响[J].实用癌症杂志, 2019, 34(4):561-563.
 PESTA M, KUCERA R, TOPOLCAN O, et al. Plasma microRNA levels combined with CEA and CA19-9 in the follow-up of colorectal cancer patients[J].Cancers(Basel), 2019, 11(6):864-878.
 LEE T, TENG T Z J, SHELAT V G. Carbohydrate antigen 19-9-tumor marker:past, present, and future[J].World J Gastrointest Surg, 2020, 12(12):468-490.
 ZHOU W, YANG F, PENG J, et al. High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy[J].J Cancer, 2019, 10(16):3810-3818.
 JIN L J, CHEN W B, ZHANG X Y, et al. Analysis of factors potentially predicting prognosis of colorectal cancer[J].World J Gastrointest Oncol, 2019, 11(12):1206-1217.
 杨少辉, 刘开泰, 赵逸斌, 等.血清YKL-40在结直肠癌诊断及筛查中的应用价值[J].现代实用医学, 2022, 34(4):465-467.
 LEHTOMAKI K, MUSTONEN H, KELLOKUMPU-LEHTINEN P L, et al. Lead time and prognostic role of serum CEA, CA19-9, IL-6, CRP, and YKL-40 after adjuvant chemotherapy in colorectal cancer[J].Cancers(Basel), 2021, 13(15):3892-3907.
 VAINER N, DEHLENDORFF C, JOHANSEN J S. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer[J].Oncotarget, 2018, 9(51):29820-29841.
 熊咏, 沈容荣, 刘东洋.血清中白细胞介素-6及癌胚抗原对结直肠癌术后复发的预测作用[J].中国当代医药, 2022, 29(2):11-14.